Skip to content

MRI on Persons With Mutations in POMT2 Gene (LGMD2N)

MRI on Persons With Mutations in POMT2 Gene (LGMD2N)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02759302
Enrollment
12
Registered
2016-05-03
Start date
2016-04-30
Completion date
2017-04-30
Last updated
2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limb-girdle Muscular Dystrophy

Keywords

MRI, LGMD, POMT2

Brief summary

POMT2 mutation is known to cause Walker Warburg Syndrome and Muscle-Brain-Eye syndrome. Recently it has been connected to limb girdle muscular dystrophy (LGMD), a disorder characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. LGMD is classified based on its inheritance pattern and genetic cause into more than 31 different types. LGMD with POMT2 mutations is a new phenotype - type 2N. Very few patients with the LGMD2N phenotype has been reported. In this study, the investigators examine five new cases with the LGMD phenotype. The primary aim is to examine the muscle involvement using MRI.

Interventions

None listed

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Persons with genetically verified mutations in POMT2

Exclusion criteria

* All contraindications for undergoing an MRI scan

Design outcomes

Primary

MeasureTime frameDescription
MRI scan for qualitative analysis of muscle involvementOne MRI scan per subject (exam lasts approximately 60 min.)The MRI protocol include T1-weighted brain and whole body examination. Four cross-sectional slices at shoulder, lumbar back, thigh and calf are chosen for qualitative analysis using the grading scale from 1 to 4 developed by Mercuri et al. (2007) to evaluate the involvement of muscles by looking at the fat infiltration.

Secondary

MeasureTime frameDescription
10 meter walk testExam last approximately 5 minMeasurement of the time it takes to walk 10 meters.
Neurological examination and test of muscle strengthExam last approximately 15 min.Muscle strength (in arms and legs) will be examined by the principal investigator based on the Medical Research Council (MRC) scale with values spanning from 5(=normal strength) to 1(=No contraction).
QuestionnairesData will be collected once for patients with LGMD2N (exam last approximately 45 min.)Data will be collected using Minimal mental examination (MMSE)
Muscle BiopsyOne muscle biopsy per subject (last approximately 15 min.)One muscle biopsy from each patient from the tibialis anterior muscle or the deltoid muscle will be analyzed for glycosylated α-dystroglycan, merosin and POMT2. (Concentration determined by standard biochemical analysis).
Forced Vital Capacity (FVC)Exam last approximately 15 minFVC is measured as the best of three attempts using a hand-held spirometer.
Electromyography (EMG)Exam last approximately 30 minEMG is used for measuring nerve conducting velocity and neuromuscular activity with repetitive stimulation (3Hz).
Heart examinationExam last approximately 45 minEchocardiography and Electrocardiogram (ECG).

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026